Pharma Reviews: India looks expensive with downgraded earnings; underweight on IT, pharma: JPMorgan

Adrian Mowat, JPMorgan is underweight on IT, pharma and consumer staples ... He feels India is an expensive market with downgraded earnings.
Read more: India looks expensive with downgraded earnings; underweight on IT, pharma: JPMorgan